Telaprevir Receives Quick FDA Review | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Better Drugs, Hep C Testing and Baby Boomers

Back to News Homepage
Next

Anemia from Hepatitis C Drugs May Be Genetically Determined

Telaprevir Receives Quick FDA Review

The Editors at Hepatitis Central
January 25, 2011

Print this page

Likely due to its ability to dramatically improve the Hepatitis C cure rate, Vertex’s telaprevir will get a priority review by the FDA.

FDA awards Vertex speedy review for hepatitis C drug

Boston Business Journal – by Julie M. Donnelly

Thursday, January 20, 2011

Vertex Pharmaceuticals Incorporated says the U.S. Food and Drug Administration has informed the company that it will make an approval decision on its drug target to treat hepatitis C by May 23rd. The FDA decided to give the company a so-called priority review for the drug, because it treats a disease where there is a high unmet medical need. This shortens the review period to six months from the usual 10 months.

Continue reading this entire article:
http://www.bizjournals.com/boston/news/2011/01/20/fda-awards-vertex-speedy-review-for.html

No Comments - be the first!
Share
Share
Previous

Better Drugs, Hep C Testing and Baby Boomers

Back to News Homepage
Next

Anemia from Hepatitis C Drugs May Be Genetically Determined

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.